Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Lundbeck completes two phase III trials of nalmefene for alcohol dependence

Jan. 3, 2011

Preliminary phase Ib/IIa data presented on ibudilast in opioid addiction

Dec. 15, 2010

Orexo's new sublingual tablet formulation of buprenorphine/naloxone completes phase I trial

Dec. 15, 2010

Aoxing Pharma begins trial of sublingual buprenorphine/naloxone for opioid addiction

Dec. 13, 2010

Alkermes presents phase II data on ALKS-33 in alcohol dependence

Dec. 10, 2010

CBLB-502 receives FDA orphan drug status for prevention of death following irradiation

Dec. 1, 2010

Enrollment completed in Nabi Biopharma' second phase III NicVAX trial

Nov. 10, 2010

Nicotine vaccine NIC-002 enters phase II study

Nov. 8, 2010

AEOL-10150 promotes survival in nonhuman primates exposed to radiation

Nov. 5, 2010

Soligenix presents preliminary phase Ib safety data on RiVax

Nov. 4, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026